Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceuticals group Hikma Pharmaceuticals forecast its generics business to generate revenue toward the top end of guidance following a 'good' start to the new year that was in line with its expectations.
Full year generics revenue was now expected towards the top end of its guidance range of $770 million to $810 million and core operating margin to be around 20%.
'We have also seen continued demand for certain COVID-19 related products, and a good performance from recent launches, which is more than offsetting increased competition on certain products, in line with our expectations,' the company said.
It maintained full-year guidance for its injectables and branded businesses.
Injectables core revenue is expected to grow in the mid-single digits and core operating margin to be in the range of 37% to 38%.
Branded revenue growth in constant currency is forecast in the mid-single digits.
Interim results for the six months to 30 June 2021 would be released on 6 August 2021.